Ultragenyx Nabs FDA Nod for First Gene Therapy

Ultragenyx (RARE) shares are rising in premarket after the FDA granted accelerated approval for its gene therapy Genglycos (DTX401). The approval materially improves near-term commercialization optionality for the therapy and is driving positive investor reaction to the stock.

Analysis

Ultragenyx (RARE) shares are rising in premarket after the FDA granted accelerated approval for its gene therapy Genglycos (DTX401). The approval materially improves near-term commercialization optionality for the therapy and is driving positive investor reaction to the stock.